Drug Trial Radar · NCT06981806
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jan 2026
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Arsen OsipovAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed after SOC chemotherapy.
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
BalixafortideDrug
Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly
BalixafortideDrug
Dose: 11 mg/kg Route: IV (2hr) Frequency: Weekly
CosibelimabDrug
Dose: 800 mg Route: IV (60 min) Frequency: Weekly
BalixafortideDrug
Dose: 16 mg/kg Route: IV (2hr) Frequency: Weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD of BalixafortideTime frame: 2 Years
- RP2D of BalixafortideTime frame: 2 Years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Cancer at SOCC
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.